{"transactions":[{"id":1595763,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B Preferred Stock","published_at":"2024-03-05T16:05:35.000Z","date":"2024-03-04","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.1,"value":10000.0,"ownership":{"direct":true},"balance_after":130000,"source":{"system":"sec-edgar","filing":"0001683168-24-001322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000168316824001322/ownership.xml","form_type":"4"}},{"id":1649132,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B Preferred Stock","published_at":"2024-02-12T16:05:15.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.1,"value":2000.0,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001683168-24-000879","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000168316824000879/ownership.xml","form_type":"4"}},{"id":2382116,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B Preferred Stock","published_at":"2022-02-22T13:07:24.000Z","date":"2022-02-18","kind":"disposition_to_issuer","acquired":false,"shares":990000,"price":0.1,"value":99000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Dr. Slilaty returned 990,000 shares of Series B Preferred Stock to the Issuer for a redemption price equal to the stated value of $0.10 per share."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001683168-22-001185","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000168316822001185/ownership.xml","form_type":"4"}},{"id":2858978,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-16T12:30:03.000Z","date":"2021-01-06","kind":"grant","acquired":true,"shares":20000000,"price":0.001,"value":20000.0,"ownership":{"direct":true},"balance_after":23343461,"source":{"system":"sec-edgar","filing":"0001128732-21-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873221000002/primary_doc.xml","form_type":"4"}},{"id":3084926,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-07-10T13:26:24.000Z","date":"2019-12-31","kind":"other","acquired":true,"shares":323673,"price":0.001,"value":323.673,"ownership":{"direct":false,"nature":"Held by TRT Pharma Inc., an entity controlled by the Reporting Person."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective December 31, 2019, Advanomics Corporation, a entity controlled by the Reporting Person, effectuated a consolidation with 4019318 Canada, Inc., an entity controlled by the Chief Financial Officer of the Issuer.  The resulting consoildated entity changed its name to TRT Pharma Inc.  The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. of which the Reporting Person is a control person."},{"field":"shares","element":"transactionShares","label":"F1","text":"The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Effective December 31, 2019, Advanomics Corporation, a entity controlled by the Reporting Person, effectuated a consolidation with 4019318 Canada, Inc., an entity controlled by the Chief Financial Officer of the Issuer.  The resulting consoildated entity changed its name to TRT Pharma Inc.  The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. of which the Reporting Person is a control person."}],"balance_after":861209,"source":{"system":"sec-edgar","filing":"0001128732-20-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873220000003/primary_doc.xml","form_type":"4"}},{"id":3084925,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-07-10T13:26:24.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":1300000,"price":0.001,"value":1300.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person."}],"balance_after":3343461,"source":{"system":"sec-edgar","filing":"0001128732-20-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873220000003/primary_doc.xml","form_type":"4"}},{"id":3084924,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-07-10T13:26:24.000Z","date":"2019-10-20","kind":"grant","acquired":true,"shares":1100000,"price":0.001,"value":1100.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person."}],"balance_after":2043461,"source":{"system":"sec-edgar","filing":"0001128732-20-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873220000003/primary_doc.xml","form_type":"4"}},{"id":3099737,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series \"B\" Preferred Stock","published_at":"2020-06-25T14:19:44.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":500000,"price":0.1,"value":50000.0,"ownership":{"direct":true},"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001128732-20-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873220000002/primary_doc.xml","form_type":"4"}},{"id":3407840,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-09-23T09:45:33.000Z","date":"2019-09-02","kind":"grant","acquired":true,"shares":13000000,"price":0.001,"value":13000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective February 1, 2019, the Issuer effectuated a reverse stock split wherein 1 share of Common Stock was issued for each 20 shares of the issued and outstanding Common Stock of the Issuer resulting in Reporting Person owning 5,869,219 shares of Common Stock of the Issuer as of that date."}],"balance_after":18869219,"source":{"system":"sec-edgar","filing":"0001128732-19-000024","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873219000024/primary_doc.xml","form_type":"4"}},{"id":3815493,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-09-14T10:08:59.000Z","date":"2018-08-27","kind":"grant","acquired":true,"shares":38000000,"price":0.001,"value":38000.0,"ownership":{"direct":true},"balance_after":117384373,"source":{"system":"sec-edgar","filing":"0001128732-18-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873218000011/primary_doc.xml","form_type":"4"}},{"id":3881362,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-06-28T17:47:21.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":27000000,"price":0.001,"value":27000.0,"ownership":{"direct":true},"balance_after":79384373,"source":{"system":"sec-edgar","filing":"0001128732-18-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873218000006/primary_doc.xml","form_type":"4"}},{"id":4213598,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-09-08T09:28:11.000Z","date":"2017-07-20","kind":"grant","acquired":true,"shares":14000000,"price":0.001,"value":14000.0,"ownership":{"direct":true},"balance_after":52384373,"source":{"system":"sec-edgar","filing":"0001128732-17-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873217000031/primary_doc.xml","form_type":"4"}},{"id":4520552,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2016-12-15T19:45:08.000Z","date":"2016-12-06","kind":"grant","acquired":true,"shares":26000000,"price":0.001,"value":26000.0,"ownership":{"direct":true},"balance_after":38384373,"source":{"system":"sec-edgar","filing":"0001128732-16-000036","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873216000036/primary_doc.xml","form_type":"4"}},{"id":4565362,"issuer":{"id":8329,"kind":"organization","name":"Sunshine Biopharma Inc."},"owners":[{"id":93478,"kind":"person","name":"Slilaty Steve N.","position":1,"cik":"0001474684","reported_name":"Slilaty Steve N.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2016-11-07T11:41:04.000Z","date":"2016-10-10","kind":"other","acquired":false,"shares":136861968,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Owned by Advanomics Corporation, an entity controlled by Reporting Person."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"136,861,968 shares owned by Advanomics Corporation, an entity controlled by Reporting Person, were disposed of pursuant to a share exchange with an unrelated party; no consideration was received as a result of the share exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"136,861,968 shares owned by Advanomics Corporation, an entity controlled by Reporting Person, were disposed of pursuant to a share exchange with an unrelated party; no consideration was received as a result of the share exchange."}],"balance_after":215014224,"source":{"system":"sec-edgar","filing":"0001128732-16-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474684/000112873216000030/primary_doc.xml","form_type":"4"}}]}